Eurofins’ US Transplant Diagnostics is proud to announce the successful acquisition of the Hawaii Cellular Therapy and Transplant Laboratory (HCTTL). HCTTL will merge with Eurofins VRL, a market leader in US pre-transplant testing, and expand VRL’s substantial US geographic footprint. The addition of this highly regarded and long-standing pillar of the Hawaiian transplant community will further increase VRL’s network of laboratories that are now located in 11 states, serving Organ Procurement Organizations, Tissue Banks, and commercial companies needing testing for donated biological materials.
Thompson Street Capital Partners (TSCP), a private equity firm based in St. Louis, announced today that it has completed the sale of Analytical Lab Group (ALG), an industry-leading microbiology and viral lab, to Element Materials Technology (Element), one of the world’s largest providers of materials and product qualification testing, inspection and certification services to the global aerospace, transportation & industrials, connected technologies, energy, and fire & building products sectors. ALG’s team of 130 scientists and experts operates a number of FDA and EPA compliance focused laboratories in San Francisco, Minneapolis and Boston and has built a strong reputation in the infection prevention market, offering comprehensive testing solutions in the molecular cell biology and virology testing, antimicrobial, pharmaceutical, medical device, biotech and healthcare industries, backed by sound regulatory and scientific expertise.
Dotmatics Ltd., a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, has today announced that it has entered into an agreement to acquire BioBright LLC, a leader in automating the flow of data from laboratory instruments to a secure cloud. BioBright is a privately-owned scientific lab data automation company based in Boston, MA, dedicated to creating the smart laboratory of the future driven by the move to data-centric research. The company’s solutions enable scientists to automate the collection of data from in-house and externally networked sources, and then standardize and analyze crucial experimental data with validation and integrity checks built in. It began operations in 2015 and was funded early on by the Defense Advanced Research Projects Agency to create a secure data collection platform for complex biological data.
Pfingsten announces its portfolio company, Full Spectrum Group, LLC (“FSG”), has acquired the assets of the Third Party Field Service Division of Pion Inc. (“Pion TFPS”), a brand-agnostic provider of repair, maintenance, validation, and qualification services for laboratory instrumentation. Headquartered in Benson, North Carolina, Pion TFPS serves a diverse nationwide customer base in biotechnology, life sciences, pharmaceutical, and other end markets. Pion TFPS represents FSG’s first acquisition since Pfingsten became the majority shareholder in February 2019.
COVID-19 testing startup Curative Inc. announced today that it has completed the acquisition of KorvaLabs, Inc., a CLIA certified and DEA licensed analytical laboratory based in San Dimas, California. The acquisition arrives just months after the two organizations first partnered to begin manufacturing and processing Curative’s oral fluid-based COVID-19 test. To date, the company has processed 245,371 tests in total with support from KorvaLabs, and continues to process approximately 14,000 on a daily basis. “KorvaLabs has been instrumental in enabling us to quickly scale our testing capacity and deliver accurate, easy-to-use oral fluid tests to thousands of people across the City and County of Los Angeles,” said Fred Turner, CEO and founder of Curative. “Curative has worked in close partnership with KorvaLabs for months now, so our decision to move forward with the acquisition just serves to formalize that relationship.”
Water Street Healthcare Partners, a strategic investor focused exclusively on the health care industry, announced today that it has signed a definitive agreement to invest in Solvias AG. Headquartered in the biotech hub of Basel, Switzerland, Solvias is one of the largest independent pharmaceutical laboratory platforms in Europe. Water Street, which has years of experience in the pharmaceutical services sector, will partner with the company’s management team to build Solvias into a premier global pharmaceutical laboratory services business.
Healthcare artificial intelligence firm Tempus announced last week the acquisition of Akesogen, the owner of a commercial laboratory and provider of genomics and clinical trial precision medicine services. Tempus said that the acquisition strengthens its expansion into disease areas outside of cancer and provides it with strategic capabilities in addition to those provided by its Chicago laboratory. Financial and other terms of the deal were not disclosed. Tempus noted that Akesogen’s CLIA-compliant and CAP-accredited lab provides a range of testing services, including for inherited risk of cancer, microbiome profiling, whole-genome genotyping, and epigenomic methylation profiling. Further, its services include providing high-throughput biomarker profiling, and microarray, sequencing, genomics, microbiome, and epigenomics analysis utilizing different types of markers.
Oncology Pharma, Inc. (OTC: ONPH) announced Wednesday that it has signed a Letter of Intent (LOI) to acquire at least a 50% stake in Diagnomics, Inc., a private CLIA certified & CAP accredited private molecular Genomics lab in San Diego, CA (USA). Included in the acquisition is Diagnomics’ partial of minority stake in EONE-Diagnomics Genome Center in Seoul South Korea. EONE-Diagnomics was one of the most successful biotech IPOs (2018) on the KOSDAQ exchange. The LOI is the first step in Oncology Pharma’s initiative to build a strategic and growing presence in the global healthcare market.
Canopy Biosciences, LLC announced Wednesday the acquisition of Core Diagnostics, a leading CLIA-certified provider of biomarker analysis services for biopharmaceutical researchers. With the acquisition of Core Diagnostics, Canopy Biosciences will be able to perform its multi-omic immune profiling services in the highly regulated CLIA environment. In addition to NanoString transcriptional profiling, Core Diagnostics also offers histopathology services including immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH). The acquisition of Core Diagnostics follows the acquisition of Zellkraftwerk, GmbH, which joined Canopy earlier this year. Both acquisitions were made possible by strategic growth investments from Ampersand Capital Partners.
Discovery Life SciencesTM (Discovery) today announced the acquisition of QualTek Molecular Laboratories (QualTek), a renowned provider of immunohistochemistry (IHC) services with CAP/CLIA-accredited and Good Laboratory Practice-(GLP) capable laboratories in California and Pennsylvania, respectively. QualTek’s acquisition significantly augments Discovery’s existing histopathology services and creates a uniquely powerful suite of solutions that include one of the world’s largest commercial biorepositories and biospecimen procurement networks, the HudsonAlpha Discovery sequencing and bioinformatics laboratory, and innovative flow cytometry and cell-based laboratory services.
What We Do
Who We Are
How We Work
Who We Help
Get In Touch
Connect With Us
Subscribe to Our Daily Note
We publish a Daily Note that aggregates M&A activity, notable developments, regulatory changes, and conferences we deem to be of interest to our partners. It is a quick afternoon read and an easy way to keep your finger on the pulse of the healthcare space. Please fill in your name and email address below if you wish to subscribe.